Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Jakub Kaczor and Peter Smith | Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning, Sonic AI
Home
/
Outcomes Rocket
/
Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning
Outcomes Rocket
Notify me
•
Jul 9, 2026
•
24:08
Interview
Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning
From
Outcomes Rocket
Jakub Kaczor and Peter Smith
(Vice President and Senior Vice President, Lumanity, guest)
Get the full transcript next time Outcomes Rocket releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Focused pharmaceutical R&D strategies often lead to internal product competition, undermining the portfolio's overall commercial potential and confusing customers.
Effective 'co-positioning' requires a structured, market-led process to identify distinct patient segments for each asset, a strategy that should ideally begin early in clinical development.
Organizational alignment is critical for success; companies must overcome 'brand ego' by establishing clear portfolio ownership and aligning incentives with total portfolio performance, not just individual brand success.
With a potential $300 billion patent cliff looming by 2030, the pressure to maximize revenue from follow-on assets makes mastering portfolio co-positioning an urgent strategic imperative for pharma companies.
Continue your research
Keep pulling the thread on Jakub Kaczor and Peter Smith.
The Paradox of R&D Focus
Strategic Co-Positioning as a Solution
11
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
11
Related
Loading transcript...
Processed Jul 9, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini